c-Rel is a member of the NF-κB (Nuclear Factor kappa-light-chain-enhancer of activated B cells) transcription factor family that plays critical roles in immune response, cell survival, and neuroinflammation. Encoded by the REL gene, c-Rel is unique among NF-κB family members for its restricted expression pattern and specific functions in immune cells and neurons. c-Rel has emerged as a key regulator of neuroinflammatory processes that contribute to neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis[1][2].
The NF-κB family comprises five members: p65 (RelA), RelB, c-Rel (Rel), p50/p105 (NF-κB1), and p52/p100 (NF-κB2). Each forms various homodimers and heterodimers with distinct transcriptional targets and biological functions. c-Rel primarily forms heterodimers with p50 and p52, and its activity is tightly regulated by IκB proteins and post-translational modifications[3][4].
c-Rel (590 amino acids, ~68 kDa) contains distinct functional domains:
| Domain | Position | Function |
|---|---|---|
| RHD (Rel Homology Domain) | 1-296 | DNA binding, dimerization, IκB interaction |
| Transactivation Domain (TAD) | 297-400 | Transcriptional activation |
| C-terminal Region | 401-590 | Regulatory functions, post-translational modifications |
c-Rel recognizes the κB DNA consensus sequence 5'-GGGRNNYYCC-3' (R=purine, Y=pyrimidine). Its binding affinity and specificity are influenced by dimer composition and post-translational modifications[5].
In immune cells, c-Rel regulates genes essential for:
Within the central nervous system, c-Rel participates in:
c-Rel is constitutively active in certain neuronal populations and responds to various stimuli including glutamate, oxidative stress, and inflammatory cytokines[6].
c-Rel activation occurs through multiple pathways:
c-Rel plays a complex role in Alzheimer's disease pathogenesis[7]:
Elevated c-Rel Activity:
Mechanisms:
Therapeutic Implications:
In Parkinson's disease, c-Rel contributes to dopaminergic neuron degeneration:
Findings:
Mechanisms:
Therapeutic Targeting:
c-Rel is implicated in ALS pathogenesis:
Dysregulation:
Pathogenic Mechanisms:
In demyelinating disease:
| Approach | Mechanism | Development Status |
|---|---|---|
| NF-κB Inhibitors | Broad IKK inhibition | Preclinical |
| c-Rel Specific Inhibitors | Block DNA binding | Research stage |
| IκB Mimetics | Stabilize IκB proteins | Preclinical |
| Antioxidants | Inhibit ROS-dependent activation | Clinical trials |
c-Rel has potential as a disease biomarker:
| Partner | Interaction Type | Functional Outcome |
|---|---|---|
| p50 (NFKB1) | Dimerization | DNA binding, transcriptional regulation |
| p52 (NFKB2) | Dimerization | Alternative pathway signaling |
| IκBα | Binding | Cytoplasmic sequestration |
| IκBβ | Binding | Cytoplasmic sequestration |
| CBP/p300 | Co-activator | Transcriptional enhancement |
| HDAC1 | Co-repressor | Transcriptional repression |
NF-κB signaling in inflammation. Signal Transduction and Targeted Therapy. 2023. ↩︎
NF-κB as a therapeutic target in neurodegenerative diseases. Neurobiology of Disease. 2022. ↩︎
Shared principles in NF-κB signaling. Cell. 2022. ↩︎
30 years of NF-κB: a blossoming of relevance to human disease. Cell. 2021. ↩︎
Regulation and function of NF-κB transcription factors in the immune system. Annual Review of Immunology. 2023. ↩︎
Roles for NF-κB in the nervous system. Cell. 2020. ↩︎
NF-κB signaling in Alzheimer's disease pathogenesis. Nature Reviews Neuroscience. 2023. ↩︎